if1

Kif15-IN-2 is a kinesin Kif15 inhibitor with potential anticancer activity and can be used in prostate cancer research.

Kif15-IN-1 is a kinesin family 15 (Kif15) inhibitor with antiproliferative activity and potential anticancer activity, which can be used to study gastric cancer.

KIF18A-IN-13 (Compound 16) is an effective oral KIF18A inhibitor with in vivo anticancer properties. It can be utilized for the research of ovarian cancer.

KIF18A-IN-14 (Compound Example 81) is an inhibitor of KIF18A that exists in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit the viability of OVCAR-3 cells with IC50 values of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be utilized in tumor research, including studies on colon cancer, breast cancer, and lung cancer.

KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, both with an IC50 range of 0.01-0.1 μM. These compounds inhibit the viability of OVCAR-3 cells, with IC50 values of 0.01-0.1 μM for EX36-A and 0-0.01 μM for EX36-B. KIF18A-IN-15 is applicable in research on tumors, including colon, breast, and lung cancers.

KIF18A-IN-16 (Compound 15) is a polycyclic KIF18A inhibitor. It is applicable in research related to tumors, including colon cancer, breast cancer, and lung cancer.

KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A. This compound demonstrates significant anti-tumor properties.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

KIF18A-IN-4 is a moderately potent, non-competitive KIF18A inhibitor of ATP and microtubule with an IC50 of 6.16 μM. It selectively acts on many mitotic kinesins and kinases, without directly affecting microtubule protein assembly, and shows anti-tumour effects.

KIF18A-IN-3 is an efficient KIF18A inhibitor (IC50 = 61nM) that induces mitotic arrest and increases the number of mitotic cells in tumor tissues. It can be used in tumor research.

KIF18A-IN-7 is an orally active inhibitor targeting KIF18A, demonstrating potent inhibition with an IC50 value of 9.4 nM against the microtubule-dependent ATPase activity of KIF18A.

KIF18A-IN-10 (Compound 24) is a potent inhibitor of KIF18A with an IC50 value of 3.8 nM. It exhibits anticancer activity with IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells.

HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in anticancer studies.

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).